Related Experiment Videos
Taming platelets with cyclic nucleotides
U R Schwarz1, U Walter, M Eigenthaler
1Institut für Klinische Biochemie und Pathobiochemie, Medizinische Universitätsklinik, Josef-Schneider Str. 2, 97080, Würzburg, Germany.
Insights
Platelet activation contributes to cardiovascular diseases. Cyclic nucleotides like cAMP and cGMP inhibit platelet function by targeting key signaling pathways, offering potential therapeutic strategies for thrombotic disorders.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Pharmacology
Background:
- Pathologic platelet activation exacerbates cardiovascular diseases.
- Platelet function regulation is crucial for cardiovascular health and therapy.
- Physiological antagonists and vasodilators inhibit platelet function via cyclic nucleotides.
Purpose of the Study:
- To explore the role of cyclic nucleotides in regulating platelet function.
- To understand the molecular mechanisms by which cyclic nucleotides inhibit platelet activation.
- To identify therapeutic targets for cardiovascular and thrombotic disorders.
Main Methods:
- Investigated the effects of cyclic AMP (cAMP) and cyclic GMP (cGcGMP) on platelet signaling pathways.
- Analyzed the impact of cyclic nucleotides on protein kinase activation and substrate phosphorylation.
- Examined the influence of cyclic nucleotides on cytoskeletal organization and calcium signaling in platelets.
Main Results:
- Elevated cAMP and cGMP levels interfere with major platelet activation pathways.
- Cyclic nucleotides inhibit signaling cascades including phospholipase C, protein kinase C, and MAPK pathways.
- These effects lead to reduced calcium mobilization and cytoskeletal rearrangements essential for platelet function.
Conclusions:
- Cyclic nucleotides are potent inhibitors of platelet activation through multiple signaling mechanisms.
- Targeting cyclic nucleotide pathways offers a promising strategy for treating thrombotic and cardiovascular diseases.
- Understanding these pathways can lead to novel therapeutic interventions for cardiovascular disorders.
Abstract:
Cardiovascular diseases are often accompanied and aggravated by pathologic platelet activation. Tight regulation of platelet function is an essential prerequisite for intact vessel physiology or effective cardiovascular therapy. Physiological platelet antagonists as well as various pharmacological vasodilators inhibit platelet function by activating adenylyl and guanylyl cyclases and increasing intracellular cyclic AMP (cAMP) and cyclic GMP (cGMP) levels, respectively. Elevation of platelet cyclic nucleotides interferes with basically all known platelet activatory signaling pathways, and effectively blocks complex intracellular signaling networks, cytoskeletal rearrangements, fibrinogen receptor activation, degranulation, and expression of pro-inflammatory signaling molecules. The major target molecules of cyclic nucleotides in platelets are cyclic nucleotide-dependent protein kinases that mediate their effects through phosphorylation of specific substrates. They directly affect receptor/G-protein activation and interfere with a variety of signal transduction pathways, including the phospholipase C, protein kinase C, and mitogen-activated protein kinase pathways. Regulation of these pathways blocks several steps of cytosolic Ca(2+) elevation and controls a multitude of cytoskeleton-associated proteins that are directly involved in organization of the platelet cytoskeleton. Due to their multiple sites of action and strong inhibitory potencies, cyclic nucleotides and their regulatory pathways are of particular interest for developing new approaches for the treatment of thrombotic and cardiovascular disorders.